introduc number adjust pt
provid increment belief worst key businesss
segment tavr diabet might behind us rev
consensu estim part due f/
 benefit guidanc constant currenc revenu growth
maintain rev rang introduc
rev pt get adjust accordingli
thing like quarter
tavr rev grew rang impli share gain especi ou
biz turn corner growth y/i world-wide
growth rang math impli abl revers
share loss prior quarter
approx user train although exact split vs ou
clear sensor manufactur issu seem abat compani
indic backlog sensor remind
patient pap pipelin compani expect regulatori approv
guardian connect stand-alone sensor result launch
therebi open new target market stand-alone cgm segment
covidien synergi realiz per origin guidanc
thing unclear us
beat larg extent due fx therefor obscur
guidanc weak cvg mitg rtg growth expect
compani indic product anniversari along tougher comp
would yield lower growth rate diabet growth expect doubl
digit impli continu adopt along new focu guardian
diabet biz expect grow mid-high teen
clear us much growth due organ pull-through demand
vs bolu growth anima patient shift
view critic import understand dynam
ebit mgn took step-up gross margin impact
bp howev unclear us fx normal impact bp
uptick ebit margin compani expect ebit mgn bp
consist maintain sinc launch op mgn assumpt
forecast unrealist
risk-shar strategi one keep eye current cover
cvg rev hospit
expect emerg market form key growth driver
design come lower margin abl reconcil
expect henc maintain neutral stanc
medtron report highlight continu effort posit compani strateg pillar therapi
innov global econom valu revenu higher consensu
estim howev key compon beat tune came fx pleas note
growth rate ep number report besid guidanc growth
delin constant currenc non-gaap number believ lead inconsist metric
comparison across compani cvg revenu world-wide y/i ou
mitg rev y/i ou rtg rev
 ou final dg rev y/i ou emerg
market grew driven growth middl east africa latin america double-digit revenu
growth china eastern europ geograph develop market grew japan us
western europ compani exud confid manufactur woe relat diabet
biz mitig upcom launch guardian connect stand-alone sensor would allow tap
new target market import highlight quarterli busi perform includ low growth rate
tavr segment impli gain share ou time biz grew y/i
includ growth compani cite increas accept intelli platform along
evolv workflow algorithm snapshot report data point consist compani
report indic share gain respect segment
figur order actual vs estim mm y/i growth rate variou divis
page
figur varianc analysi number mm
page
figur quarterli growth rate cvg mitg rtg dg segment
page
thing mention note
perhap highlight call chang tone uptak compani indic
user activ compani indic product issu sensor
resolv back order system math indic prioriti access
program patient transit close thereof regulatori approv
guardian connect stand-alon cgm allow compani launch product
number indic handili beat guidanc mid-teen growth rate segment
growth expect tick specif height contribut
would organ jump demand vs suppli anima patient pump
tavr bright spot within cvg growth percent ou growth
impli gain back share primarili due recent launch evolut evolut
total synergi save realiz far covidien deal highlight howev consist
guidanc call indic total synergi covidien deal
recogn end
organ revenu growth expect rang cvg mitg rtg
expect grow diabet expect grow low double-digit stronger first half
low comparison total compani revenu expect consist annual guidanc
oper margin expect improv bp driven intern initi
final expect exclud potenti final million payment
puerto rico relat pend litig
page
maintain market perform rate continu posit view fundament introduc
number adjust pt appropri remain long-term name view
strategi one-stop shop provid product servic hospit bundl fashion appeal
strategi howev p/ compound-annual-growth-rate believ stock fairli valu henc remain
sidelin concern stori remain front highlight initi report
aggress expect opex synergi
page
statement oper
number mm round
good sold
amort intang
sg
page
oper countri largest pure-play medic devic world
compani re-domicil ireland post covidien acquisit
use tradit dcf discount rate top-lin growth rate consist
compani guidanc investor day lead us intrins valu around
risk achiev price target
repeal uncertainti especi
compani abl achiev goal top-lin growth opex synergi cash flow
compani activ bear fruit
geopolit currenc movement affect stori
suraj kalia certifi view express report accur reflect person view
subject compani secur part compens directli
indirectli relat specif recommend view express report
